On the genesis and prognosis of variant translocations in chronic myeloid leukemia

Cancer Genetics and Cytogenetics

Volumn 173, Issue 2, 2007, Pages 97-106

  Gorusu, Madhavi ^a   Benn, Peter ^a   Li, Zihai ^a   Fang, Min ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GENETICS; CANCER GROWTH; CANCER PATIENT; CHROMOSOME 9Q; CHROMOSOME DELETION; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HUMAN; LABORATORY TEST; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS;

CHROMOSOME BANDING; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOID, CHRONIC; MODELS, GENETIC; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 33847149254     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.10.006     Document Type: Article

References (47)

1. Rowley J.D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973) 290-293
2. Huret J.L. Complex translocations, simple variant translocations and Ph-negative cases in chronic myelogenous leukaemia. Hum Genet 85 (1990) 565-568
3. Dobrovic A., Morley A.A., Seshadri R., and Januszewicz E.H. Molecular diagnosis of Philadelphia negative CML using the polymerase chain reaction and DNA analysis: clinical features and course of M-bcr negative and M-bcr positive CML. Leukemia 5 (1991) 187-190
4. Hagemeijer A., de Klein A., Godde-Salz E., Turc-Carel C., Smit E.M., van Agthoven A.J., and Grosveld G.C. Translocation of c-abl to "masked" Ph in chronic myeloid leukemia. Cancer Genet Cytogenet 18 (1985) 95-104
5. Yehuda O., Abeliovich D., Ben-Neriah S., Sverdlin I., Cohen R., Varadi G., Orr R., Ashkenazi Y.J., Heyd J., Lugassy G., and Ben Yehuda D. Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph-negative and variant Ph-positive. Cancer Genet Cytogenet 114 (1999) 100-107
6. Reddy K.S., and Sulcova V. A FISH study of variant Philadelphia rearrangements. Cancer Genet Cytogenet 118 (2000) 121-131
7. Fitzgerald P.H., and Morris C.M. Complex chromosomal translocations in the Philadelphia chromosome leukemias: serial translocations or a concerted genomic rearrangement?. Cancer Genet Cytogenet 57 (1991) 143-151
8. O'Brien S., Thall P.F., and Siciliano M.J. Cytogenetics of chronic myelogenous leukaemia. Baillieres Clin Haematol 10 (1997) 259-276
9. Sessarego M., Fugazza G., Canepa L., Bacigalupo A., Bruzzone R., and Patrone F. Fluorescence in situ hybridization provides evidence for two-step rearrangement in a masked Ph chromosome formation. Leuk Res 19 (1995) 921-925
10. El-Zimaity M.M., Kantarjian H., Talpaz M., O'Brien S., Giles F., Garcia-Manero G., Verstovsek S., Thomas D., Ferrajoli A., Hayes K., Nebiyou Bekele B., Zhou X., Rios M.B., Glassman A.B., and Cortes J.E. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 125 (2004) 187-195
11. Johansson B., Fioretos T., and Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107 (2002) 76-94
12. Sandberg A.A. Chromosomes and causation of human cancer and leukemia: XL. The Ph1 and other translocations in CML. Cancer 46 (1980) 2221-2226
13. Loncarevic I.F., Romer J., Starke H., Heller A., Bleck C., Ziegler M., Fiedler W., Liehr T., Clement J.H., and Claussen U. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia. Genes Chromosomes Cancer 34 (2002) 193-200
14. Potter A.M., Watmore A.E., Cooke P., Lilleyman J.S., and Sokol R.J. Significance of non-standard Philadelphia chromosomes in chronic granulocytic leukaemia. Br J Cancer 44 (1981) 51-54
15. Reid A.G., Huntly B.J., Grace C., Green A.R., and Nacheva E.P. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol 121 (2003) 419-427
16. Bernstein R., Pinto M.R., Wallace C., Penfold G., and Mendelow B. The incidence, type, and subsequent evolution of 14 variant Ph1 translocations in 180 South African patients with Ph1-positive chronic myeloid leukemia. Cancer Genet Cytogenet 12 (1984) 225-238
17. Sinclair P.B., Nacheva E.P., Leversha M., Telford N., Chang J., Reid A., Bench A., Champion K., Huntly B., and Green A.R. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95 (2000) 738-743
18. Huntly B.J., Reid A.G., Bench A.J., Campbell L.J., Telford N., Shepherd P., Szer J., Prince H.M., Turner P., Grace C., Nacheva E.P., and Green A.R. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98 (2001) 1732-1738
19. Kolomietz E., Al-Maghrabi J., Brennan S., Karaskova J., Minkin S., Lipton J., and Squire J.A. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 97 (2001) 3581-3588
20. Costa D., Carrio A., Madrigal I., Arias A., Valera A., Colomer D., Aguilar J.L., Teixido M., Camos M., Cervantes F., and Campo E. Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia. Cancer Genet Cytogenet 166 (2006) 89-93
21. Grand F., Kulkarni S., Chase A., Goldman J.M., Gordon M., and Cross N.C. Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia. Cancer Res 59 (1999) 3870-3874
22. Markovic V.D., Bouman D., Bayani J., Al-Maghrabi J., Kamel-Reid S., and Squire J.A. Lack of BCR/ABL reciprocal fusion in variant Philadelphia chromosome translocations: a use of double fusion signal FISH and spectral karyotyping. Leukemia 14 (2000) 1157-1160
23. Albano F., Specchia G., Anelli L., Zagaria A., Storlazzi C.T., Buquicchio C., Roberti M.G., Liso V., and Rocchi M. Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases. Genes Chromosomes Cancer 36 (2003) 353-360
24. Zagaria A., Anelli L., Albano F., Vicari L., Schiavone E.M., Annunziata M., Pane F., Liso V., Rocchi M., and Specchia G. Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia. Cancer Genet Cytogenet 167 (2006) 97-102
25. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., and Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
26. Quintas-Cardama A., Kantarjian H., Talpaz M., O'Brien S., Garcia-Manero G., Verstovsek S., Rios M.B., Hayes K., Glassman A., Bekele B.N., Zhou X., and Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105 (2005) 2281-2286
27. Sinclair P.B., Green A.R., Grace C., and Nacheva E.P. Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. Blood 90 (1997) 1395-1402
28. Naumann S., and Decker H.J. Genesis of variant Philadelphia chromosome translocations in chronic myelocytic leukemia. Cancer Genet Cytogenet 147 (2003) 18-22
29. Ishihara T., and Minamihisamatsu M. The Philadelphia chromosome: considerations based on studies of variant Ph translocations. Cancer Genet Cytogenet 32 (1988) 75-92
30. Li Z., Qiao Y., Liu B., Laska E.J., Chakravarthi P., Kulko J.M., Bona R.D., Fang M., Hegde U., Moyo V., Tannenbaum S.H., Menoret A., Gaffney J., Glynn L., Runowicz C.D., and Srivastava P.K. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 11 (2005) 4460-4468
31. Bonifazi F., de Vivo A., Rosti G., Guilhot F., Guilhot J., Trabacchi E., Hehlmann R., Hochhaus A., Shepherd P.C., Steegmann J.L., Kluin-Nelemans H.C., Thaler J., Simonsson B., Louwagie A., Reiffers J., Mahon F.X., Montefusco E., Alimena G., Hasford J., Richards S., Saglio G., Testoni N., Martinelli G., Tura S., Baccarani M., Europena Study Group on Interferon in Chronic Myeloid Leukemia, Italian Cooperative Study Group on CML, France Intergroup of CML, German CML Study Group, UK Medical Research Council Working Party on CML, Spanish CML Study Group, Australian CML Study Group, and Swedish CML Study Group. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood 98 (2001) 3074-3081
32. Maness L.J., and McSweeney P.A. Treatment options for newly diagnosed patients with chronic myeloid leukemia. Curr Hematol Rep 3 (2004) 54-61
33. Hughes T., and Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 20 (2006) 29-41
34. Branford S., Rudzki Z., Harper A., Grigg A., Taylor K., Durrant S., Arthur C., Browett P., Schwarer A.P., Ma D., Seymour J.F., Bradstock K., Joske D., Lynch K., Gathmann I., and Hughes T.P. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 17 (2003) 2401-2409
35. Fisher A.M., Strike P., Scott C., and Moorman A.V. Breakpoints of variant 9;22 translocations in chronic myeloid leukemia locate preferentially in the CG-richest regions of the genome. Genes Chromosomes Cancer 43 (2005) 383-389
36. Haltrich I., Kost-Alimova M., Kovacs G., Krivan G., Tamaska J., Klein G., Fekete G., and Imreh S. Jumping translocation of 17q11∼qter and 3q25∼q28 duplication in a variant Philadelphia t(9;14;22)(q34;q32;q11) in a childhood chronic myelogenous leukemia. Cancer Genet Cytogenet 164 (2006) 74-80
37. Anelli L., Albano F., Zagaria A., Liso A., Roberti M.G., Rocchi M., and Specchia G. A chronic myelocytic leukemia case bearing deletions on the three chromosomes involved in a variant t(9;22;11). Cancer Genet Cytogenet 148 (2004) 137-140
38. Storlazzi C.T., Specchia G., Anelli L., Albano F., Pastore D., Zagaria A., Rocchi M., and Liso V. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. Genes Chromosomes Cancer 35 (2002) 271-276
39. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., Gathmann I., Bolton A.E., van Hoomissen I.C., Goldman J.M., Radich J.P., and International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 (2003) 1423-1432
40. Cohen N., Rozenfeld-Granot G., Hardan I., Brok-Simoni F., Amariglio N., Rechavi G., and Trakhtenbrot L. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 128 (2001) 114-119
41. Lee D.S., Lee Y.S., Yun Y.S., Kim Y.R., Jeong S.S., Lee Y.K., She C.J., Yoon S.S., Shin H.R., Kim Y., and Cho H.I. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression. Genes Chromosomes Cancer 37 (2003) 291-299
42. Xinh P.T., Vu H.A., Nghia H., Binh N.T., Be T.V., Binh T.V., Tokunaga K., and Sato Y. Coexistence of Philadelphia chromosome positive cells with and without der(9) deletion in a patient with chronic myelogenous leukemia. Cancer Genet Cytogenet 164 (2006) 122-127
43. Rudduck-Sivaswaren C., Tien S.L., Lim P., Lim E., Lie D.K., Tan P.H., and Lee A.S. Evidence for deletion of 9q as a two-step process in chronic myeloid leukemia. Clin Genet 68 (2005) 461-465
44. Dewald G.W., Wyatt W.A., and Silver R.T. Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy. Leuk Lymphoma 34 (1999) 481-491
45. Herens C., Tassin F., Lemaire V., Beguin Y., Collard E., Lampertz S., Croisiau C., Lecomte M., De Prijk B., Longree L., and Koulischer L. Deletion of the 5′-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients. Br J Haematol 110 (2000) 214-216
46. Primo D., Tabernero M.D., Rasillo A., Sayagues J.M., Espinosa A.B., Chillon M.C., Garcia-Sanz R., Gutierrez N., Giralt M., Hagemeijer A., San Miguel J.F., and Orfao A. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia 17 (2003) 1124-1129
47. Aoun P., Wiggins M., Pickering D., Foran J., Rasheed H., Pavletic S.Z., and Sanger W. Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis. Cancer Genet Cytogenet 154 (2004) 138-143